- Home
- BMA vs NAMS Comparison
BMA vs NAMS Comparison
Compare BMA & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BMA | NAMS |
|---|---|---|
| Founded | 1966 | 2019 |
| Country | Argentina | Netherlands |
| Employees | N/A | 100 |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 3.7B |
| IPO Year | 2006 | N/A |
Fundamental Metrics
Financial Performance| Metric | BMA | NAMS |
|---|---|---|
| Price | $89.63 | $29.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $99.33 | $46.75 |
| AVG Volume (30 Days) | 201.3K | ★ 961.2K |
| Earning Date | 05-27-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.99% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.25 | $17.96 |
| Revenue Next Year | N/A | $540.65 |
| P/E Ratio | $33.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $38.30 | $21.14 |
| 52 Week High | $106.15 | $42.21 |
Technical Indicators
Market Signals| Indicator | BMA | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 47.61 | 41.00 |
| Support Level | $85.47 | $29.23 |
| Resistance Level | $94.50 | $37.29 |
| Average True Range (ATR) | 4.46 | 1.88 |
| MACD | -0.39 | -0.42 |
| Stochastic Oscillator | 27.12 | 8.00 |
Price Performance
Historical ComparisonAbout BMA Banco Macro S.A. ADR (representing Ten Class B)
Banco Macro SA is a financial institution and it provides standard banking products and services designed to suit individual needs. It has two categories of customers, retail customers, which include individuals and entrepreneurs, and corporate customers, which include small, medium, and large companies and corporations. In addition, it provides services to four provincial governments. The company generates the majority of its revenue from Argentina.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.